Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus

Cancer Gene Therapy

Volumn 17, Issue 12, 2010, Pages 883-892

  Ahmed, M ^a   Puckett, S ^a   Lyles, D S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; IL 12; tumor therapy; VSV

Indexed keywords

INTERLEUKIN 12; MATRIX PROTEIN; MUTANT PROTEIN; ONCOLYTIC VIRUS; RM51R M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-12; MICE; MUTANT PROTEINS; MUTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VESICULOVIRUS; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 78349304039     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.46     Document Type: Article

References (47)

1. Dodwell D, Williamson D. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. Cancer Treat Rev 2008; 34: 137-144.
2. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S. Metastatic breast cancer: an updating. Biomed Pharmacother 2006; 60: 548-556.
3. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004; 330: 34-49.
4. Balachandran S, Barber GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000; 50: 135-138.
5. Balachandran S, Barber GN. Oncloytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol 2001; 75: 3474-3479.
6. Cesaire R, Oliere S, Sharif-Askari E, Loignon M, Lezin A, Olindo S et al. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene 2005; 25: 349-358.
7. Ebert O, Harbaran S, Shinozaki K, Woo SLC. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 2004; 12: 350-358.
8. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SL. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003; 63: 3605-3611.
9. Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SL. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther 2003; 8: 434-440.
10. Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV\{delta\}M51) on multifocal and invasive gliomas. J Natl Cancer Inst 2006; 98: 1546-1557.
11. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003; 77: 8843-8856.
12. Shin EJ, Wanna G, Choi B, Aguila DI, Ebert O, Genden EM et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 2007; 117: 210-214.
13. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
14. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275.
15. Wollmann G, Robek MD, van den Pol AN. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol 2007; 81: 1479-1491.
16. Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. J Virol 2000; 74: 1513-1523.
17. Gaddy DF, Lyles DS. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 2005; 79: 4170-4179.
18. Kopecky SA, Willingham MC, Lyles DS. Matrix protein and another viral component contribute to induction of apopto-sis in cells infected with vesicular stomatitis virus. J Virol 2001; 75: 12169-12181.
19. Koyama AH. Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res 1995; 37: 285-290.
20. Bell JC, Lichty B, Stojdl DF. Getting oncolytic virus therapies off the ground. Cancer Cell 2003; 4: 7-11.
21. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of M protein of vesicular stomatitis virus to suppress interferon beta gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 2003; 77: 4646-4657.
22. Ahmed M, Brzoza KL, Hiltbold EM. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 2006; 80: 2194-2205.
23. Ahmed M, Mitchell LM, Puckett S, Brzoza-Lewis KL, Lyles DS, Hiltbold EM. M protein mutant vesicular stomatitis virus stimulates maturation of TLR7-positive dendritic cells through TLR-dependent and-independent mechanisms. J Virol 2009; 83: 2962-2975.
24. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895-904.
25. Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008; 8: 228.
26. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15: 50-65.
27. Mahvi DM, Henry MB, Albertini MR, Weber SM, Meredith K, Schalch H et al. Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial. Cancer Gene Ther 2007; 14: 717-723.
28. Shan D, Chen L, Njardarson JT, Gaul C, Ma X, Danishefsky SJ et al. Synthetic analogues of migrastatin that inhibit mammary tumor metastases in mice. Proc Natl Acad Sci USA 2005; 102: 3772-3776.
29. Shi H, Weiguo Z, Rong L, Abraham S, Kittrell FS, Medina D et al. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 2001; 61: 6945-6951.
30. Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang N-S et al. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 2002; 1: 949-957.
31. Weber SM, Qi C, Neal Z, Sondel PM, Mahvi DM. IL-12 cDNA direct injection: antimetastatic effect from a single injection in a murine hepatic metastases model. J Surg Res 2004; 122: 210-217.
32. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang N-S. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000; 7: 826-838.
33. Ahmed M, Marino TR, Puckett S, Kock ND, Lyles DS. Immune response in the absence of neurovirulence in mice infected with M protein mutant vesicular stomatitis virus. J Virol 2008; 82: 9273-9277.
34. Chiocca EA. The host response to cancer virotherapy. Curr Opin Mol Ther 2008; 10: 38-45.
35. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Exp Opin Biol Ther 2007; 7: 1705-1721.
36. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
37. Sung CK, Choi B, Wanna G, Genden EM, Woo S, Shin EJ. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope 2008; 118: 237-242.
38. Kelly BJ, Fleeton MN, Atkins GJ. Potential of alphavirus vectors in the treatment of advanced solid tumors. Recent Patents Anticancer Drug Discov 2007; 2: 159-166.
39. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza R. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 2007; 67: 9371-9379.
40. Pulaski B, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 2000; 49: 34-45.
41. Chen L, Hang T-G, Meseck M, Mandeli J, Fallon J, Woo S. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mo Ther 2007; 15: 2194-2202.
42. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67: 2840-2848.
43. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006; 15: 865-874.
44. Takeda K, Hayakawa Y, Atsuta M, Hong S, Van Kaer L, Kobayashi K et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 2000; 12: 909-914.
45. Chiesa MD, Romagnani C, Thiel A, Moretta L, Moretta A. Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood 2006; 108: 3851-3858.
46. Schattner A, Rager-Zisman B. Lysis by natural killer cells requires viral replication and glycoprotein expression. Immunol Lett 1986; 13: 261-268.
47. Carey BL, Ahmed M, Puckett S, Lyles DS. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol 2008; 82: 12104-12115.